Medical device company Hemovent GmbH reported on Monday the receipt of the CE marking for its MOBYBOX Runner Controller, to market the product throughout the heart and lung support market in the EU.
The company said the Runner is designed to slingshot clinicians into a new era of mobility and ease of use. The device is designed for Extracorporeal Life Support (ECLS) applications, including Extracorporeal CardioPulmonary Resuscitation (ECPR) to treat patients in cardiac arrest or profound circulatory shock.
Following the Runner EU regulatory approval, the company has created an entirely new solution for the extreme challenges of ECLS deployment in situations with unpredictable and severely restricted emergency environments, said Oliver Marseille, PhD, chief technology officer of Hemovent and a co-founder of CircuLite (Heartware International) prior to co-founding Hemovent.
In 2019, the company receive the CE mark for the MOBYBOX System with the Master Controller and is currently in preparing a post market clinical follow-up trial.
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist
GEN and Sulfateq report positive Phase 1 data for SUL-238 in Alzheimer's